The National Medical Products Administration has approved the market launch of an innovative drug.

Recently, the National Medical Products Administration approved the marketing of injection Fosdemab, reported by Tianjing Biological Pharmaceuticals Co., Ltd. This product is used in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma who have previously received at least one line of treatment. The market launch of this product offers new treatment options for relevant patients.